Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Added to Busulfan and Fludarabine Conditioning Regimen in Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation
NCT03247088Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2017
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose and Progression-Free Survival up to 6 years. Started Jul 2017; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03247088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247088.